Searchable abstracts of presentations at key conferences in endocrinology

ea0044p97 | Diabetes and Cardiovascular | SFEBES2016

SGLT2 inhibitors: results from clinical practice

Border Daniel K. , Barber Thomas M.

Introduction: There is growing real-world experience of the SGLT2 inhibitor class for type 2 diabetes mellitus (T2D). We performed an audit of clinico-biochemical effects of SGLT2 inhibitor use for patients with diabesity in the context of a tier-3 obesity service within a UK-based teaching hospital.Methods: We included patients with a confirmed diagnosis of T2D who had been treated with an SGLT2 inhibitor within licensed indications (monotherapy and add...

ea0044p178 | Obesity and Metabolism | SFEBES2016

Dramatic weight loss induced by dapagliflozin and tier 3 obesity service support

Border Daniel K , Barber Thomas M

The importance of weight reduction in the management of diabesity is well-established. However, significant weight loss can be difficult to achieve without bariatric surgery, even within specialist tier 3 obesity services. Here we describe the case of a 52 year old man who presented to weight management clinic. He had made multiple weight loss attempts, but with little success. On presentation, his weight was 140.8 kg with a BMI of 40.3 kg/m2, and he had now been static at thi...

ea0050p336 | Obesity and Metabolism | SFEBES2017

Metabolic phenotype of Male Obesity-associated Secondary Hypogonadism pre- and post-replacement therapy with intra-muscular Testosterone undecanoate therapy

Dimitriadis Georgios K , Randeva Harpal S , Grammatopoulos Dimitris K , Barber Thomas M

Aim: To explore the metabolic phenotype of Male Obesity-associated Secondary Hypogonadism (MOSH) and following treatment with long-acting intramuscular (IM) testosterone undecanoate.Methods: A prospective observational pilot study on metabolic effects of IM testosterone undecanoate in MOSH (Hypogonadal [HG] group, n=13), including baseline comparisons with controls (Eugonadal [EG] group, n=15). Half the subj...

ea0050p336 | Obesity and Metabolism | SFEBES2017

Metabolic phenotype of Male Obesity-associated Secondary Hypogonadism pre- and post-replacement therapy with intra-muscular Testosterone undecanoate therapy

Dimitriadis Georgios K , Randeva Harpal S , Grammatopoulos Dimitris K , Barber Thomas M

Aim: To explore the metabolic phenotype of Male Obesity-associated Secondary Hypogonadism (MOSH) and following treatment with long-acting intramuscular (IM) testosterone undecanoate.Methods: A prospective observational pilot study on metabolic effects of IM testosterone undecanoate in MOSH (Hypogonadal [HG] group, n=13), including baseline comparisons with controls (Eugonadal [EG] group, n=15). Half the subj...

ea0007p176 | Reproduction | BES2004

The effects of thyroid hormone on cytokine-induced proliferation in human trophoblast cells

Barber K , Khanim F , McCabe C , Bulmer J , Whitley G , Franklyn J , Kilby M

Thyroid hormones are essential for optimum fetal neurodevelopment. In-utero nutrition is dependant on adequate placentation. Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) have been demonstrated to affect proliferation of human trophoblast and may therefore play a role in adequate human placentation. Intrauterine growth restriction (a process associated with malplacentation) is associated with fetal hypothyroxinemia and enhanced thyroid receptor (TR) expressi...